{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:13:44Z","timestamp":1786115624964,"version":"build-2736575974"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adenine deaminase (ADAR) is a key RNA editing enzyme that plays an important role in the initiation and progression of cancer. However, the mechanisms regulating its protein stability and its function in glioblastoma (GBM) remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study systematically investigated the expression patterns of ADAR across pan-cancer types and its specific mechanisms in GBM through the integration of multi-omics data analysis and experimental validation. We performed bioinformatics analysis on the TCGA dataset, utilising single-cell RNA sequencing data,\n                      <jats:italic>in vitro<\/jats:italic>\n                      functional experiments, and molecular studies including co-immunoprecipitation and ubiquitination detection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found that ADAR exhibits significant differential expression across various cancers and is closely associated with tumour mutation burden and survival outcomes. Further analysis revealed that ADAR is highly expressed in GBM and primarily enriched in tumour cells, with its expression levels significantly positively correlated with key cancer signalling pathways such as PI3K-AKT-mTOR and G2M checkpoints. Functional experiments confirmed that ADAR significantly promotes the migratory capacity of glioblastoma cells. Importantly, we identified E3 ubiquitin ligase STUB1 as a specific regulator of ADAR, which mediates ADAR\u2019s proteasome-dependent degradation by promoting K48-linked ubiquitination of ADAR. Knocking down STUB1 significantly upregulates ADAR protein levels and enhances tumour cell migration capacity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This newly identified STUB1-ADAR regulatory axis not only elucidates the molecular mechanisms underlying ADAR homeostasis but also provides new potential strategies for targeted therapy against glioblastoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1827793","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T04:25:24Z","timestamp":1785990324000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting ADAR stability: a novel approach to combat glioblastoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Qin","family":"Fei","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, The Third People\u2019s Hospital of Chengdu","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jueru","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, The Third People\u2019s Hospital of Chengdu","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, The Third People\u2019s Hospital of Chengdu","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, The Third People\u2019s Hospital of Chengdu","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, The Third People\u2019s Hospital of Chengdu","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.3c00433","article-title":"Adenosine deaminase acting on RNA (ADAR) enzymes: a journey from weird to wondrous","volume":"56","author":"Keegan","year":"2023","journal-title":"Acc Chem Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13578-024-01216-6","article-title":"RNA editing enzymes: structure, biological functions and applications","volume":"14","author":"Zhang","year":"2024","journal-title":"Cell Bioscience"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.18632\/aging.204853","article-title":"Clinical significance, tumor immune landscape and immunotherapy responses of ADAR in pan-cancer and its association with proliferation and metastasis of bladder cancer","volume":"15","author":"Yu","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2024.152855","article-title":"Pan-cancer analysis of ADAR1 with its prognostic relevance in low-grade glioma","volume":"229","author":"Yang","year":"2024","journal-title":"Immunobiology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e21822","DOI":"10.7759\/cureus.21822","article-title":"Reclassification of glioblastoma multiforme according to the 2021 World Health Organization classification of central nervous system tumors: a single institution report and practical significance","volume":"14","author":"Stoyanov","year":"2022","journal-title":"Cureus"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/02688697.2021.1907306","article-title":"The prognosis of glioblastoma: a large, multifactorial study","volume":"35","author":"Luo","year":"2021","journal-title":"Br J Neurosurg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"686","DOI":"10.21037\/atm.2019.11.06","article-title":"ADAR, the carcinogenesis mechanisms of ADAR and related clinical applications","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann Trans Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-021-02271-9","article-title":"ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism","volume":"22","author":"Tassinari","year":"2021","journal-title":"Genome Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cells11050851","article-title":"Ubiquitination-proteasome system (UPS) and autophagy two main protein degradation machineries in response to cell stress","volume":"11","author":"Li","year":"2022","journal-title":"Cells"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-020-01281-8","article-title":"Ubiquitin\u2013proteasome system (UPS) as a target for anticancer treatment","volume":"43","author":"Park","year":"2020","journal-title":"Arch Pharmacal Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040902","article-title":"Drug development targeting the ubiquitin\u2013proteasome system (UPS) for the treatment of human cancers","volume":"12","author":"Zhang","year":"2020","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/nyas.14206","article-title":"The E3 ubiquitin ligase CHIP in normal cell function and in disease conditions","volume":"1460","author":"Wang","year":"2020","journal-title":"Ann N Y Acad Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115190","article-title":"STUB1\/CHIP: New insights in cancer and immunity","volume":"165","author":"Liu","year":"2023","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B14","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.01.011","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"1","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030736","article-title":"The emerging roles of RNA modifications in glioblastoma","volume":"12","author":"Dong","year":"2020","journal-title":"Cancers"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/9315027","article-title":"The interplay between RNA editing regulator ADAR1 and immune environment in colorectal cancer","volume":"2023","author":"Zheng","year":"2023","journal-title":"J Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-022-02051-5","article-title":"STUB1-SMYD2 axis regulates drug resistance in glioma cells","volume":"72","author":"Pan","year":"2022","journal-title":"J Mol Neurosci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxac072","article-title":"E3 ubiquitin ligases STUB1\/CHIP contributes to the Th17\/Treg imbalance via the ubiquitination of aryl hydrocarbon receptor in rheumatoid arthritis","volume":"209","author":"Wang","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-03-2073","article-title":"Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population","volume":"64","author":"Brat","year":"2004","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/35050618","article-title":"The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins","volume":"3","author":"Connell","year":"2001","journal-title":"Nat Cell Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nature04600","article-title":"CHIP-mediated stress recovery by sequential ubiquitination of substrates and Hsp70","volume":"440","author":"Qian","year":"2006","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.251531398","article-title":"Underediting of glutamate receptor GluR-B mRNA in Malignant gliomas","volume":"98","author":"Maas","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1172\/jci62925","article-title":"Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells","volume":"122","author":"Choudhury","year":"2012","journal-title":"J Clin Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4172","article-title":"Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulation","volume":"22","author":"Stellos","year":"2016","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109500","article-title":"ADAR1 interaction with Z-RNA promotes editing of endogenous double-stranded RNA and prevents MDA5-dependent immune activation","volume":"36","author":"de Reuver","year":"2021","journal-title":"Cell Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1261\/rna.079953.124","article-title":"Multifaceted roles of RNA editing enzyme ADAR1 in innate immunity","volume":"30","author":"Jarmoskaite","year":"2024","journal-title":"Rna"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1827793\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T04:25:25Z","timestamp":1785990325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1827793\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":28,"alternative-id":["10.3389\/fonc.2026.1827793"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1827793","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"article-number":"1827793"}}